

Mass Spectrometry


A complete line of turn-key services

Innomics now offers a complete line of mass spectrometry services for all your research and drug development needs. Our laboratory is staffed by experienced scientists, equipped with cutting-edge LC-MS/MS instrumentation and advanced bioinformatics capabilities.


Simplifying the challenge of proteomic analysis, metabolomic analysis and biologics characterization

Our advanced instrumentation and state-of-the-art methods can help simplify the challenge of proteomic analysis, metabolomics analysis and biologics characterization. We provide services for biomarker discovery, drug target deconvolution, mechanism of action (MOA), candidate ligand screening, and comprehensive characterization of biologics.

	Discovery Proteomics	Candidate Screening	Molecular Characterization	Process Development
Proteomics				
Protein Identification	•			
Proteome and PTM Profiling	•			
Quantitative Proteomics	•	•		
Biologics Characterization				
Higher Order Structure		•	•	
Intact Mass (Native MS)		•	•	•
Peptide Mapping			•	•
Product Purity				•



With you throughout the whole process



We provide scientific expertise to aid with experimental design, bioinformatics analysis, and long-term planning for comprehensive solutions that will support drug development pipelines from discovery through process development.

Proteomics and biologics characterization specialists supply our mass spectrometry services. Accurate and timely project completion is our top priority, and we do this by focusing on both precision and service.



Quality Data



Fast



Cost Effective

State-of-the-art capability

We use cutting-edge methodologies to achieve high data quality and high throughput for intact mass analysis, peptide mapping, and higher-order structure analyses.

Complex biologic drugs, bi- and multi-specific antibodies, antibody-drug conjugates, and Fc-fusion proteins can all be characterized with the help of our mass spectrometry services.



Expert Analysis

- Bi- and multi-specific antibodies
- Antibody-drug conjugates
- Fc-fusion proteins


Working with professionals instills assurance

We have experience in offering next-generation sequencing services to pharmaceutical, biotech and academic research partners. Our expertise allows us to deliver accurate and reliable results for a wide range of applications.

In addition to our NGS services, we also provide proteomic and biologics characterization services to help you accelerate your life science research and drug development projects. Using our expertise in bioinformatics innovation and the management of large-scale computing infrastructure, we offer a full range of LC-MS services.

Our mass spectrometry service facility is staffed by professionals that have worked extensively with liquid chromatography and mass spectrometry based analytical methods. The facility is equipped to handle a wide variety of proteomic research applications and biologic/protein characterization.

We have the ability to collaborate with customers and develop customized MS processes to match the specific needs of each project.





To learn more

If you have any questions or would like to discuss how our services can help you with your research, please don't hesitate to contact us at P_contact@innomics.com. We look forward to hearing from you!

Innomics Inc.
750 N. Pastoria Ave
Sunnyvale, CA 94085
USA

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
Copyright© Innomics Inc. 2023. All trademarks are the property of Innomics Inc. or their respective owners. This material contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.